Photo taken from Vivek Subbiah/LinkedIn
Aug 11, 2023, 19:30
Vivek Subbiah: Pralsetinib has received FULL FDA approval
Exciting News for RET+ patients!
Pralsetinib has received FULL FDA approval!
From treating the 1st patient in the universe to getting accelerated approval, & now full approval all based on a Phase 1/2 trial, it’s been an incredible journey.
Grateful to patients, caregivers, investigators, Blueprint Meds team, & FDA for making this now available as another option for RET+ patients with NSCLC Precision medicine for the win.
Links to the paper:
- Pre-clinical & Phase 1 tinyurl.com/2wxysehf
- RET + NSCLC tinyurl.com/y8ded4db
- RET+ Thyroid tinyurl.com/5eea36bh
- RET+ Tissue agnostic tinyurl.com/2h8rt8dy
- Full approval tinyurl.com/5t3hzbxp
Source: Vivek Subbiah / Twitter
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 21, 2024, 12:18
Dec 21, 2024, 11:52
Dec 21, 2024, 11:30
Dec 21, 2024, 11:25
Dec 21, 2024, 11:18